Join the PFDD event on 23 September 2022 together with the patient community!
This meeting will give people diagnosed with muscular dystrophy types 2A, 2C, 2D, 2E, 2F and 2I the opportunity to share with the FDA and other stakeholders the experiences and challenges of living with LGMD.
The meeting will take place virtually and live where you can respond to the survey questions by calling or writing your comments.
The EL-PFDD meeting is designed to engage patients and gather their unique perspectives. With this information, the goal is to provide information that will help the FDA review new drug applications for LGMD therapies to try to better meet the needs and expectations of our patient community.
More information and register at: https://lgmdpfdd.com/